CD8\(^+\) T-cell cross-competition is governed by peptide–MHC class I stability

Ian Galea, Jana Stasakova, Melanie S. Dunscombe, Christian H. Ottensmeier, Tim Elliott and Stephen M. Thirdborough

Cancer Sciences Unit, University of Southampton, Faculty of Medicine, Southampton General Hospital, Southampton, UK

A major contributing factor to the final magnitude and breadth of CD8\(^+\) T-cell responses to complex antigens is immunodomination, where CD8\(^+\) T cells recognizing their cognate ligand inhibit the proliferation of other CD8\(^+\) T cells engaged with the same APC. In this study, we examined how the half-life of cell surface peptide–MHC class I complexes influences this phenomenon. We found that primary CD8\(^+\) T-cell responses to DNA vaccines in mice are shaped by competition among responding CD8\(^+\) T cells for non-specific stimuli early after activation and prior to cell division. The susceptibility of CD8\(^+\) T cells to ‘domination’ was a direct correlate of higher kinetic stability of the competing CD8\(^+\) T-cell cognate ligand. When high affinity competitive CD8\(^+\) T cells were deleted by self-antigen expression, competition was abrogated. These findings show, for the first time to our knowledge, the existence of regulatory mechanisms that direct the responding CD8\(^+\) T-cell repertoire toward epitopes with high-stability interactions with MHC class I molecules. They also provide an insight into factors that facilitate CD8\(^+\) T-cell coexistence, with important implications for vaccine design and delivery.

Key words: CD8\(^+\) T cells • Competition • Immunodominance • MHC • Peptide

Supporting Information available online

Introduction

Despite the presence of high numbers of potential epitopes within a complex immunogen, the elicited CD8\(^+\) T-cell response rapidly becomes skewed toward a few epitopes [1]. These CD8\(^+\) T-cell determinants can be broadly divided into two categories, immunodominant epitopes (IDEs) and subdominant epitopes (SDEs), based upon the relative magnitude of the CD8\(^+\) T-cell populations induced. Such a restricted pattern of T-cell responses in terms of target specificity favors the emergence of viral escape mutants and limits the effectiveness of CD8\(^+\) T-cell-based genetic vaccines [2–5]. The mechanisms behind immunodominance are multifold and include differences in CD8\(^+\) T-cell precursor frequency, epitope abundance on the priming APCs, and competition between CD8\(^+\) T cells for activation [1, 6]. This study focuses on the last factor, defined as immunodominination, and asks how the kinetic stability of peptide–MHC (pMHC) class I complexes influences simultaneous, competing CD8\(^+\) T-cell responses to unrelated epitopes.

While it is agreed that CD8\(^+\) T cells of the same epitope specificity can compete for their cognate ligand when expressed by a shared APC, it remains controversial whether competition between CD8\(^+\) T cells of different epitope specificity affects priming and immunodominance [7]. In experiments involving the adoptive transfer of TCR-transgenic CD8\(^+\) T cells, several studies have shown that host CD8\(^+\) T cells of different specificity
compete for APCs upon antigen challenge [8, 9], whereas others have not observed this ‘cross-competition’ phenomenon [10, 11]. In silico modeling has suggested that differences in epitope abundance and differing TCR avidities could account for some of the controversy. Scherer and colleagues [12] found that at low epitope expression levels per APC, CD8+ T cells compete for access to their cognate ligand, so there is competition between CD8+ T cells of the same but not different epitope specificity. At high epitope expression levels, however, CD8+ T cells compete for a nonspecific stimulus, namely, access to the APC surface, which is a shared resource.

The half-life of pMHC class I complexes is a key parameter that affects epitope density on the priming APC surface and subsequent CD8+ T-cell responses [13, 14]. Peptides with slow dissociation rates show increased resistance to tapasin editing during ER loading onto MHC class I molecules, leading to higher initial epitope densities on the APC [15, 16]. Furthermore, because of their inherent high stability, these pMHC complexes may persist at the cell surface during APC migration to draining lymph nodes and also promote prolonged CD8+ T-cell–APC encounters [17, 18], perhaps resulting in preferential CD8+ T-cell responses [18]. There is evidence from studies investigating the mechanisms of immunodominance that during competitive CD4+ T-cell responses, peptides with low-stability interactions with MHC class II molecules lose the ability to sustain T-cell expansion [19]. However, it is not known whether pMHC stability contributes to CD8+ T-cell competition, and if this property can be exploited to broaden responses to polyepitope vaccines. To this end we employed a model system based in part on analyses by Mylin et al. [20], who characterized the B6 (H-2b) response hierarchy to SV40 large T antigen (Tag). They identified three IDEs (designated T1, T2/3, and T4), and one SDE (designated T5) that elicits a CD8+ T-cell response in the absence of the IDEs. Here we have measured endogenous CD8+ T-cell responses to the subdominant T5 (Dα-restricted) epitope when coexpressed with kinetic-stability variants of the T4 (Kβ-restricted) epitope following immunization with plasmid DNA vectors in normal or Tag-tolerant mice. Our results demonstrate that the ability of competitive CD8+ T cells to exert immunodominance directly correlates with pMHC stability.

Results

SV40 Tag immunodominance hierarchy

In the C57BL/6 mouse, immunization with SV40 Tag-transformed cells or a recombinant vaccinia virus encoding full-length Tag induces a CD8+ T-cell response directed against three H-2Dα-restricted peptides, designated epitopes T1, T2/3, and T5, and one H-2Kb epitope T4 in the hierarchical order T4 > T1 > T2/3 > T5 [20]. Competitive CD8+ T-cell responses have typically been observed in secondary responses, when the ratio of T cells to antigen is high [21]. To determine whether CD8+ T-cell responses induced by DNA vaccination showed similar patterns of immunodominance, C57BL/6J mice were immunized by intramuscular injection with plasmid DNA encoding amino acids 205–566 of Tag (pATag). This truncated Tag sequence encodes the four defined CD8+ T-cell epitopes but for safety excludes p53 and Rb protein-binding sites [22]. Groups of mice were also immunized with plasmid DNA encoding the nominal T1, T4, or T5 epitopes fused immediately to the N-terminal domain of Fragment C (DOM) from tetanus toxin. This vaccine design, referred to as pDOM-epitope, allowed comparison of response magnitudes to the individual CD8+ T-cell determinants in the absence of known competitive H-2d epitopes [23]. After 12 days, the number of peptide-specific CD8+ T cells induced was measured directly ex vivo by IFN-γ ELISPOT.

Immunization with pATag elicited an effector T-cell repertoire largely focused on epitopes T1 and T4 (Fig. 1A). Epitope T5-specific responses were barely detectable above background (mean 43 spot forming cells (SFCs)/10⁶ splenocytes compared to 15 with an irrelevant peptide). When the determinants were delivered individually via pDOM-epitope, intermediate responses were obtained to epitope T5 (mean 915 SFCs/10⁶ splenocytes; Fig. 1B). In addition, the T1-specific response was smaller in magnitude than that elicited by pDOM-T4 immunization (Fig. 1B). Hence, the subdominant status of T5 was lost when the epitope was expressed alone, in the context of DOM as opposed to ATag.

![Figure 1. SV40 Tag immunodominance hierarchy in WT mice primed by DNA vaccination. C57BL/6 mice were immunized with (A) pATag. (B) pDOM-epitope encoding the individual Tag-derived determinants as indicated, (C) pDOM-TSα3T1 or (D) pDOM-TSα3T4. After 12 days, the number of epitope-specific T cells induced was assayed by IFN-γ ELISPOT. The results shown are combined from two separate experiments, with each data point representing an individual mouse. Horizontal bars depict group means.](image-url)
Inter- and intra-allelic competition shapes primary CD8⁺ T-cell responses to DNA vaccines

To examine whether co-expression of an IDE with T5 would re-establish the response hierarchy, we generated a plasmid DNA construct encoding the H-2Db-restricted epitopes T1 and T5 separated by a 3-alanine spacer, appended in tandem to the C-terminus of DOM. Immunization with this vaccine elicited a primary CD8⁺ T-cell response that focused only on epitope T1 (Fig. 1C); moreover, when T5 was co-expressed with the H-2Kb-restricted epitope T4, a similar phenomenon was observed (Fig. 1D). Since the latter epitope is presented by a different class I allomorph, competition for binding to the MHC could be excluded as a possible cause of the observed immunodominance. The apparent ability of IDE-reactive T cells to impede the simultaneous expansion of T5-specific T cells suggested that primary response patterns to DNA vaccines are indeed shaped by immunodominance.

Selective thymic tolerance of IDE-reactive CD8⁺ T cells ablates competition

To test the possibility that the observed subdominance of epitope T5 was due to T-cell competition, we asked whether reducing the precursor frequency of high-affinity IDE-reactive T cells would liberate T5-specific responses from domination. For these experiments, we utilized female TRAMP (transgenic adenocarcinoma of the mouse prostate) mice transgenic for SV40 Tag [24]. In this model, Celis and colleagues have demonstrated that high-affinity T cells specific for T4 are tolerized by thymic deletion, whereas CD8⁺ T cells with high affinity for T5 survive negative selection [25]. In these mice, and consistent with the findings of Grossmann et al. [25], self-tolerance was found to limit the selection [25]. In these experiments, we utilized female TRAMP (transgenic adenocarcinoma of the mouse prostate) mice transgenic for SV40 Tag [24]. In this model, Celis and colleagues have demonstrated that high-affinity T cells specific for T4 are tolerized by thymic deletion, whereas CD8⁺ T cells with high affinity for T5 survive negative selection [25]. In these mice, and consistent with the findings of Grossmann et al. [25], self-tolerance was found to limit the selection [25].

Using the TRAMP model, we next asked whether the residual repertoire of lower-avidity T1 or T4 specific CD8⁺ T cells would still dominate responses when their cognate epitope ligand was delivered in tandem with epitope T5 (via pDOM-T5_A3T1 or pDOM-T5_A3T4). In these Tag-tolerant mice, dominance was abrogated, with both vaccines eliciting coexistent effector populations (Fig. 2C and D). Similar patterns of responses to pDOM-T5_A3T4 immunization were observed when T5/D²- and T4/Kb-tetramer binding, rather than IFN-γ ELISPOT analysis was used to quantitate T-cell priming (data not shown). These findings suggest that responses to the T5 epitope are inhibited by the immunodominant T4 response in non-transgenic mice. However, when the IDE-specific repertoire is subject to tolerance, hierarchical control by the T1 or T4 epitope is broken, and T5-specific responses are elicited. The reduced susceptibility of the SDE T5 to tolerance induction likely reflects the relatively short half-life of T5/D² complexes [20, 30], resulting in diminished steady-state epitope presentation levels and a failure to induce negative selection [27]. Moreover, when activated in the periphery, low epitope density may render the T5-specific preimmune repertoire vulnerable to competition.

Domination by IDE-reactive CD8⁺ T cells correlates with pMHC stability

To establish the relationship between T-cell competition and the kinetic stability of pMHC-complexes, we generated a series of pDOM-T5_A3T4 constructs encoding amino acid substitutions in
the anchor residues of the T4 octamer. Initially, the half-life for dissociation of these MHC variant peptides (MVPs) from H-2K^b at the cell surface was determined as a relative measure of the stability of the pMHC complex on the priming APC [15]. The half-life for dissociation of these T4 MVPs and epitope T5 are listed in Table 1, together with their capacity to stimulate CD8^+ T cells elicited by pDOM-T4 vaccination. Responses were measured to the native T4 epitope and to each of the peptide variants, and we observed no difference in the relative number of IFN-γ-producing cells when the MVPs were present at saturation (Table 1).

Relative levels of presentation of the T4 kinetic stability variants and T5 were assessed in vitro by electroporating Rauscher virus-induced H-2^b lymphoma (RMA) cells with each of the pDOM-T5A3T4 MVP constructs. Induction of β-galactosidase activity by T-cell hybridomas 2F4 and 2D11, raised against the native K\(^b\)/VVYDFLKC and D\(^b\)/QGINNLDNL complexes, respectively, was used as an indicator of the ability of the RMA cells to process and present the class I determinants from DOM. Each of the kinetic stability variants of epitope T4 was recognized by the T-cell hybridoma 2F4 (Fig. 3A), with overall activation correlating with the half-life for dissociation (Spearman: \(r = 1.00\) and \(p = 0.023\); Fig. 3B). Similarly, the T5-specific T-cell hybridoma was stimulated at a low, but detectable (eight-fold higher than background), level by each of the pDOM-T5A3T4 MVP transfectants (Fig. 3A), and compatible with the short half-life of T5/D\(^b\) complexes.

To evaluate the immunogenicity of the kinetic-stability variants relative to the native T4 epitope, and the capacity of subsequent responses to dominate T5, we immunized WT or TRAMP mice with the pDOM-T5A3T4 vaccines encoding the T4 anchor residue substitutions. Each peptide variant expanded T4-specific T cells in WT and TRAMP mice (Fig. 4). With the exception of WT responses to the slow off-rate variant C8L, the size of the effector populations correlates with pMHC stability (Fig. 5A). Similarly, there is a consistent relationship between the ability of MVP responses to dominate T5 and relative pMHC half-lives of epitope T5 versus T4-MVP (Spearman: \(r = 0.96\) and \(p = 0.023\) in WT mice, and \(r = 0.98\) and \(p = 0.001\) in TRAMP mice; Fig. 5B). Thus, highly stable variants elicited similar or enhanced competitive T4 responses, whereas variant epitopes with rapid off-rates from H-2K^b showed diminishing competitive responses, culminating in a reversal of the immunodominance hierarchy with epitope F5Y, C8G (Fig. 4).

We have previously reported that prolonged presentation of high stability pMHC complexes via pDOM-epitope delivery limits the magnitude of primary CD8^+ T-cell responses, possibly due to

### Table 1. Half-life of dissociation of epitope T4 and its variants, together with their capacity to stimulate epitope T4-specific TCD8^+

| Peptide | Sequence   | \(t_{1/2}\) (h) | Percentage of T4-specific response (1μM) |
|---------|------------|-----------------|-----------------------------------------|
| T4      | VVYDFLKC   | 1.6             | 100                                     |
| C8L     | VVYDFLKL   | 5.4             | 91                                      |
| C8I     | VVYDFLKL   | 2.9             | 91                                      |
| F5Y     | VVYDFLKC   | 0.8             | 100                                     |
| C8G     | VVYDFLKL   | 0.6             | 100                                     |
| F5Y, C8G| VVYDFLKG   | 0.3             | 85                                      |
| T5      | QGINNLNDL  | 0.9             |                                         |

© 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
supra-optimal stimulation leading to clonal deletion [16]. This previous finding is not inconsistent with the poor correlation between the slow off-rate of epitope C8L and the magnitude of the CD8$^+$ T-cell response in WT mice (Fig. 5A).

Competition occurs early after CD8$^+$ T-cell activation

Finally, we investigated the time frame of CD8$^+$ T-cell competition using a mifepristone (MFP)-responsive gene regulation system (GeneSwitch$^\text{TM}$ [31]) to temporally regulate T4 epitope expression relative to constitutive T5 epitope expression (shown schematically in Fig. 6A). C57BL/6J mice were co-injected with pGAL4-T4/CMV-T5 and pSwitch, and left untreated or administered a 5 mg/kg dose of MFP at 0 or 6 h post-immunization. Importantly, MFP at this dose does not affect the magnitude of an endogenous response to pDOM-epitope vaccination [32]. In the absence of MFP, basal leakiness of T4 transgene expression primed a T4-specific response that was lower in magnitude than that induced by uncontrolled, CMV promoter-driven T5 epitope expression (Fig. 6B cf. 1B). Conversely, when MFP was given immediately after DNA immunization, the elicited CD8$^+$ T-cell response focused on epitope T4, with diminished reactivity to epitope T5. However, when the inducer was given 6 h after immunization, the magnitude of T5-specific responses approximated those to T4 (Fig. 6B). These data suggest that cross-competition occurs early after initial CD8$^+$ T-cell activation and prior to cell division.

Discussion

This report demonstrates that primary CD8$^+$ T-cell immunodominance hierarchies to DNA vaccines are shaped by competition among CD8$^+$ T cells of different pMHC specificities, for a common stimulus, early after activation and prior to cell division. We show for the first time that the susceptibility of CD8$^+$ T cells to domination is a direct correlate of higher kinetic stability of the competing CD8$^+$ T-cell cognate ligand. In tolerant mice, an affinity advantage for the SDE-specific CD8$^+$ T-cell population compensated for lower epitope density and facilitated coexistence. These findings are compatible with immunodominant CD8$^+$ T cells in WT mice having a stimulation threshold advantage at priming, with pMHC class I stability regulating the magnitude of TCR engagement [17].
Previous studies on T-cell competition have shown that CD8+ T cells of different epitope specificity can compete with each other when epitopes are presented on shared APCs [33–36], and when the ratio of CD8+ T cells to APCs is high [8, 36–38]. It has been suggested that the resource that CD8+ T cells compete for is access to the APC itself or APC-derived factors, such as costimulatory molecules or cytokines [8]. At this time we cannot distinguish between these possibilities. However, our data together with a recent report investigating CD4+ T-cell immunodominance hierarchies [19] underline the importance of the kinetic stability of pMHC complexes in determining the final specificity of T-cell responses. Sant and colleagues found that peptides with fast dissociation rates from I-A\(^d\) initially expand CD4+ T cells, but fail to sustain their activation throughout the course of the response [19]. Importantly, this failure only manifested when the short half-life epitope was co-administered with an IDE. Thus, for both CD8+ and CD4+ T-cell responses there exist regulatory mechanisms independent of antigen processing and editing effects, which direct the responding T-cell repertoire toward epitopes with high-stability interactions with MHC molecules.

In contrast to the findings of Sant [19], our model requires the IDE to be expressed in the first 6 h following DNA delivery in order for competition to occur. This time scale is similar to that previously reported after adoptive transfer experiments, in which competing TCR transgenic CD8+ T cells needed to be present in the first few hours to interfere with endogenous CD8+ T-cell responses [38]. These findings suggest that competition occurs at the stage of CD8+ T-cell recruitment into the response. Experiments using multiphoton intravital microscopy to describe initial, synchronized CD8+ T-cell-DC encounters in lymph nodes have shown that CD8+ T-cell activation occurs in three successive phases [39]. During phase one, CD8+ T cells undergo multiple transient encounters with DCs over several hours. This is followed by a second period lasting 8–20 h, during which CD8+ T cells form stable interactions with DCs and begin to secrete cytokines. The third phase coincides with the onset of proliferation and is characterized by the return of high CD8+ T-cell mobility and brief contacts with DCs. A recent report has shown that the duration of phase one correlates inversely with the number of complexes of cognate pMHC per DC [17]. It is therefore possible that CD8+ T cells responding to high or low stability pMHC complexes differ with respect to the time required for the transition from phase one to phase two [18]. If the number of sites on an APC that can form stable interactions with CD8+ T cells are limiting, perhaps CD8+ T cells compete for progression to phase two. CD8+ T cells interact with DCs by way of bundles of microvilli on the DC surface [40]. The concentration of pertinent pMHC complexes and costimulatory molecules in these distinct membrane structures culminates in multifocal synapse assembly and stable DC–CD8+ T-cell interactions. Of relevance to immunodominance, the surface area of the DC committed to microvilli formation is limited and is likely related to DC cytoskeletal polarization during CD8+ T-cell activation [40]. Thus, it is possible that by monopolizing DC polarization, dominant CD8+ T cells prevent the coordinated delivery of signals from antigen, adhesion/costimulatory molecules, and soluble mediators to SDE-specific CD8+ T cells.

In terms of vaccine development, targeting epitopes that form low stability complexes with MHC molecules may provide a strategy to bypass tolerance to tumor self-antigens [25, 28]. However, the sensitivity of these low stability determinants to domination makes the development of improved vectors that incorporate minimal antigenic baggage, and that do not entail complex administration schedules [41], critical.

### Materials and methods

#### Plasmids

To construct the pATag vector, cDNA encoding amino acids 205–566 of Tag flanked by Not I and Xma I restriction sites was amplified by RT-PCR from 293-T cells and cloned into pCI-E3/19K [42]. The pDOM-epitope vaccines encoding the nominal Tag-derived CD8+ T-cell determinants were constructed as previously described [42]. To construct the MFP-responsive DOM-T4 expression vector, an ORF flanked by Hind III and Pme I restriction sites was amplified by PCR using pDOM-T4 as template and cloned into pGene/VS (Invitrogen, Carlsbad, CA). The GAL4/DOM-T4/BGHpA expression cassette was then PCR amplified and inserted into pDOM-T5 as a Bgl II fragment to generate the construct pGAL4-T4/CMV-T5. Plasmid DNA was purified for immunization using a QIAfilter Mega kit (Qiagen, Hilden, Germany). All cDNAs were verified by sequencing.

#### Brefeldin A decay assay

RMA-S cells were cultured overnight at 26°C in serum-free media (X-VIVO 15, Lonza, MD) and then for 60 min in the presence of BreFeldinA (BFA) and saturating concentration of peptide (10 μM). The cells were washed (×4) in X-VIVO 15 plus BFA and then cultured at 37°C. Cells were taken at the indicated times and stained with either anti-D\(^b\) (KH95) or anti-I\(^b\) (AF6-88.5) mAbs conjugated with FITC (BD Biosciences). The cells were washed twice and data were collected using a FACSCanto (BD Biosciences) cytometer and analyzed using WinMDI 2.9 software.

#### Mice and in vivo experiments

C57BL/6J TRAMP mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained in-house as a hemizygote colony. Genotyping was done by PCR on DNA isolated from ear punches according to the established protocols for the TRAMP transgene [24]. Transgenic and non-transgenic littermates were vaccinated at 11–12 weeks of age with a total of 50 μg of plasmid DNA in normal saline injected into two sites in
the quadriceps. Evaluation of peptide-specific T-cell responses was performed by ELISPOT analysis as described previously [42]. For the GeneSwitch experiments, mice were co-injected intramuscularly with 50μg pCMV-T5/GAL4-T4 and 50μg pSwitch. At 0 and 6 h after plasmid DNA injection, MFP (Sigma, Poole, UK) was given to the mice intraperitoneally at 5 mg/kg. Animal experiments were conducted according to the UK Home Office license guidelines and approved by the University of Southampton’s ethical committee.

### Hybridoma generation

Epitope T4- and T5-specific hybridomas were generated according to Sanderson and Shastri [43]. Splenocytes from C57BL/6J mice immunized with pDOM-T4 or pDOM-T5 were restimulated in vitro with the appropriate peptide for 3 days in the presence of 20 U/mL IL-2 before being fused with BWZ.36/CD8α.

### Epitope presentation assay

RMA cells were electroporated with pDOM-T5TM T4 MVP constructs using conditions described previously [42]. After 20 h, the transfectants were co-cultured with T5- or T4-specific T-cell hybridomas and LacZ activity induced measured at 570 nm using the substrate chlorophenol red-β-D-galactopyranoside (Roche, Mannheim, Germany).

### Acknowledgements:

We thank members of the biomedical facility for their technical assistance. This work was supported by the Cancer Research UK Programme grants C7056 (TE) and C491 (CHO), and a Wellcome Trust/Academy of Medical Sciences Starter Grant (IG).

### Conflict of interest:

The authors declare no financial or commercial conflict of interest.

### References

1. Yewdell, J. W. and Bennink, J. R., Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 1999. 17: 51–88.
2. Price, D. A., West, S. M., Betts, M. R., Ruff, L. E., Brenchley, J. M., Ambrozak, D. R., Edghill-Smith, Y. et al., T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 2004. 21: 793–803.
3. Sacre, K., Carcelain, G., Cassoux, N., Fillet, A. M., Costagliola, D., Vittecoq, D., Salmon, D. et al., Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J. Exp. Med. 2005. 201: 1999-2010.
4. Frahm, N., Kiepiela, P., Adams, S., Linde, C. H., Hewitt, H. S., Sango, K., Feeney, M. E. et al., Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 2006. 7: 173–178.
5. Smith, C. L., Mirza, F., Pasquetto, V., Tschinke, D. C., Palmowski, M. J., Dunbar, P. R., Sette, A. et al., Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol. 2005. 175: 8431–8437.
6. Chen, W., Anton, L. C., Bennink, J. R. and Yewdell, J. W., Dissecting the multifactorial causes of immunodominance. Immunity 2000. 12: 83–93.
7. Kedl, R. M., Kappler, J. W. and Marrack, P., Epitope dominance, competition and T cell affinity maturation. Curr. Opin. Immunol. 2003. 15: 120–127.
8. Kedl, R. M., Rees, W. A., Hildeman, D. A., Schaefer, B., Mitchell, T., Kappler, J. W. and Marrack, P., T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 2000. 192: 1105–1114.
9. Kedl, R. M., Schaefer, B. C., Kappler, J. W. and Marrack, P., T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat. Immunol. 2002. 3: 27–32.
10. Butz, E. A. and Bevan, M. J., Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 1998. 8: 167–175.
11. Probst, H. C., Dumrese, T. and van den Broek, M. F., Cutting edge: competition for APC by CTLs of different specificities is not functionally important during induction of antiviral responses. J. Immunol. 2002. 168: 5387–5391.
12. Scherer, A., Salathe, M. and Bonhoeffer, S., High epitope expression levels increase competition between T cells. PLoS Comput. Biol. 2006. 2: e109.
13. Busch, D. H. and Pamer, E. G., MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. J. Immunol. 1998. 160: 4441–4448.
14. Van Der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M. and Melief, C. J., Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 1996. 156: 3308–3314.
15. Howarth, M., Williams, A., Toilstrup, A. B. and Elliott, T., Tapasin enhances MHC class I peptide presentation according to peptide half-life. Proc. Natl. Acad. Sci. USA 2004. 101: 11737–11742.
16. Thirdborough, S. M., Roddick, J. S., Radcliffe, J. N., Howarth, M., Stevenson, F. K. and Elliott, T., Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide-MHC class I complexes. Eur. J. Immunol. 2008. 38: 364–369.
17. Henrickson, S. E., Mempei, T. R., Mazo, I. B., Liu, B., Artyomov, M. N., Zheng, H., Peixoto, A. et al., T cell sensing of antigen donor governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat. Immunol. 2008. 9: 282–291.
18. Zheng, H., Jin, B., Henrickson, S. E., Perelson, A. S., von Andrian, U. H. and Chakraborty, A. K., How antigen quantity and quality determine T-cell decisions in lymphoid tissue. Mol. Cell. Biol. 2008. 28: 4040–4051.
19. Weaver, J. M., Chaves, F. A. and Sant, A. J., Abortive activation of CD4 T cell responses during competitive priming in vivo. Proc. Natl. Acad. Sci. USA 2009. 106: 8647–8652.
20. Mylin, L. M., Bonnaud, R. H., Lippolis, J. D. and Tevethia, S. S., Hierarchy among multiple H-2 restriction cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 1995. 69: 6665–6677.
21. Kastemuller, W., Gasteiger, G., Gronau, J. H., Baier, R., Ijapoci, R., Busch, D. H. and Drexler, I., Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J. Exp. Med. 2007. 204: 2187–2198.
22 Xie, Y. C., Hwang, C., Overwijk, W., Zeng, Z., Eng, M. H., Mule, J. J., Imperiale, M. J. et al., Induction of tumour antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J. Natl. Cancer Inst. 1999. 91: 169–175.

23 Rice, J., Elliott, T., Buchan, S. L. and Stevenson, F. K., DNA fusion vaccine designed to induce cytototoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J. Immunol. 2001. 167: 1558–1565.

24 Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R. et al., Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 1995. 92: 3439–3443.

25 Grossmann, M. E., Davila, E. and Celis, E., Avoiding tolerance against prosthetic antigens with subdominant peptide epitopes. J. Immunother. 2001. 24: 237–241.

26 Schell, T. D., Knowles, B. B. and Tevethia, S. S., Sequential loss of cytototoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res. 2000. 60: 3002–3012.

27 Schell, T. D., In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in Simian virus 40 T-antigen-transgenic mice. J. Virol. 2004. 78: 1751–1762.

28 Ryan, C. M. and Schell, T. D., Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. J. Immunol. 2006. 177: 255–267.

29 Rice, J., Ottensmeier, C. H. and Stevenson, F. K., DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 2008. 8: 108–120.

30 Fu, T-M., Mylin, L. M., Schell, T. D., Back, I., Russ, G., Yewdell, J. W., Bennink, J. R. and Tevethia, S. S., An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytototoxic T-lymphocyte epitope. J. Virol. 1998. 72: 1469–1481.

31 Wang, Y., O’Malley, B. W., Jr., Tsai, S. Y. and O’Malley, B. W., A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA 1994. 91: 8180–8184.

32 Radcliffe, J. N., Roddick, J. S., Stevenson, F. K. and Third borough, S. M., Prolonged antigen expression following DNA vaccination impairs effector CD8+ T-cell function and memory development. J. Immunol. 2007. 179: 8313–8321.

33 Sandberg, J. K., Gruufman, P., Wolpert, E. Z., Franksson, L., Chambers, B. J. and Karre, K., Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery. J. Immunol. 1998. 160: 3163–3169.

34 Wolpert, E. Z., Gruufman, P., Sandberg, J. K., Tegnesjo, A. and Karre, K., Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J. Immunol. 1998. 161: 4499–4505.

35 Gruufman, P., Sandberg, J. K., Wolpert, E. Z. and Karre, K., Immunization with dendritic cells breaks immunodominance in CTL responses against minor histocompatibility and synthetic peptide antigens. J. Leukoc. Biol. 1999. 66: 268–271.

36 Gruufman, P., Wolpert, E. Z., Sandberg, J. K. and Karre, K., T cell competition for the antigen-presenting cell as a model for immunodominance in the cytototoxic T lymphocyte response against minor histocompatibility antigens. Eur. J. Immunol. 1999. 29: 2197–2204.

37 Roy-Proulx, G., Meunier, M. C., Lanteigne, A. M., Brochu, S. and Perreault, C., Immunodomination results from functional differences between competing CTL. Eur. J. Immunol. 2001. 31: 2284–2292.

38 Willis, R. A., Kappler, J. W. and Marrack, P. C., CD8+ T-cell competition for dendritic cells in vivo is an early event in activation. Proc. Natl. Acad. Sci. USA 2006. 103: 12063–12068.

39 Mempel, T. R., Henrickson, S. E. and von Andrian, U. H., T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004. 427: 154–159.

40 Fisher, P. J., Bulur, P. A., Vuk-Pavlovic, S., Prendergast, F. G., and Dietz, A. B., Dendritic cell microvilli: a novel membrane structure associated with the multifocal synapse and T cell clustering. Blood 2008. 112: 5037–5045.

41 Liu, J., Ewald, B. A., Lynch, D. M., Nanda, A., Sumida, S. M. and Barouch, D. H., Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J. Virol. 2006. 80: 11991–11997.

42 Radcliffe, J. N., Roddick, J. S., Friedmann, P. S., Stevenson, F. K. and Thirdborough, S. M., Prime-boost with alternating DNA vaccines designed to engage different antigen-presentation pathways generates high frequencies of peptide-specific CD8+ T cells. J. Immunol. 2006. 176: 6626–6633.

43 Sanderson, S. and Shastri, N., LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 1994. 6: 369–376.

Abbreviations: IDE: immunodominant epitope · MFP: mifepristone · MVP: MHC variant peptide · DOM: N-terminal domain of Fragment C from tetanus toxin · pMHC: peptide–MHC · SDE: subdominant epitope · Tag: SV40 large T antigen · TRAMP: transgenic adenocarcinoma of the mouse prostate

Full correspondence: Dr. Stephen M. Thirdborough, Cancer Research UK Centre, Somers Cancer Research Building, MP 824, Southampton General Hospital, Southampton, SO16 6YD, UK
Fax: +44-23-8079-5152
E-mail: S.M.Thirdborough@soton.ac.uk

Received: 5/8/2011
Revised: 8/9/2011
Accepted: 11/10/2011
Accepted article online: 17/10/2011